Health CarePharmaceuticals & Biotechnology
  • Price (EUR)107.75
  • Today's Change4.00 / 3.86%
  • Shares traded322.91k
  • 1 Year change-23.15%
  • Beta0.9349
Data delayed at least 15 minutes, as of Oct 23 2020 16:39 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

  • Revenue in EUR (TTM)1.01bn
  • Net income in EUR80.11m
  • Incorporated1999
  • Employees1.28k
  • Location
    Galapagos NVGeneraal De Wittelaan 3MALINES (MECHELEN) 2800BelgiumBEL
  • Phone+32 15342900
  • Fax+32 15342901
  • Websitehttp://www.glpg.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Hutchison China MediTech Limited176.62m-93.05m3.60bn853.00--12.12--20.37-0.1255-0.12550.23780.37990.410411.204.74188,308.40-21.25-8.48-29.29-11.7421.1629.16-51.79-16.403.01--0.0818---4.3118.60-41.73--18.09--
Idorsia Ltd64.20m-420.43m3.75bn636.00--10.85--58.40-3.38-3.380.51462.230.0569--12.00---37.35---41.49-------656.18-----439.780.6455---60.71---27.75------
Evotec SE470.34m27.98m3.77bn3.28k123.727.3285.478.010.18620.18623.123.150.416540.685.37155,227.102.406.752.818.9325.9730.515.7713.632.406.450.50710.0018.9237.91-54.77--43.29--
Dechra Pharmaceuticals plc566.39m37.28m4.25bn1.81k108.946.0434.067.500.32730.32734.985.900.4521.995.32284,900.402.972.973.353.3456.6156.286.585.942.396.670.3577110.286.9120.4162.2011.7467.2515.15
Swedish Orphan Biovitrum AB (publ)1.50bn299.03m4.47bn1.47k14.612.409.092.9810.4510.4552.4063.700.40481.647.5611,662,920.008.0710.699.4413.6378.0372.9219.9420.190.41699.020.41480.0055.9140.4536.65--121.42--
H. Lundbeck A/S2.35bn230.32m5.18bn5.84k22.432.659.922.208.628.6287.9972.930.61181.654.813,012,401.
Orion Oyj1.10bn239.60m5.37bn3.42k22.337.0318.074.891.711.717.815.421.081.756.71336,049.0023.5720.1428.1725.7461.3260.2021.8320.852.47200.600.124795.627.520.69361.52-1.05-8.492.90
STADA Arzneimittel AG2.81bn253.04m6.36bn12.34k25.106.2413.582.264.064.0645.1416.340.63682.134.93253,193.506.075.458.549.0851.4451.529.538.100.93426.560.720210.6811.924.81-1.3836.212.2339.84
Hikma Pharmaceuticals Plc1.93bn432.58m6.48bn8.58k15.794.0612.083.351.621.627.236.290.60511.733.92204,903.9013.571.7519.922.3752.4452.2022.433.081.1213.370.3279152.656.128.1572.3411.829.5316.51
Ipsen SA2.71bn-49.00m6.71bn5.81k--3.5844.582.48-0.5986-0.597432.5022.350.59922.365.02466,127.10-1.127.30-1.6810.1581.7980.30-1.879.850.891622.850.34636.9814.6715.11-114.17--27.163.30
Vifor Pharma AG1.76bn150.83m6.84bn2.73k45.362.2213.743.892.492.4928.9850.750.40232.073.76675,161.105.435.706.758.0259.4944.7813.4912.761.5313.250.147580.0218.47-11.294.40-10.9714.275.92
Galapagos NV1.01bn80.11m7.04bn1.28k154.502.5473.416.960.69740.697417.1142.500.2807--27.571,008,929.002.22-0.8022.50-0.9104----7.92-3.76--1.320.0097--181.8658.34612.13--74.74--
Croda International Plc1.47bn227.94m8.88bn4.58k38.928.2829.296.041.611.6110.377.570.67332.495.52291,681.2010.4513.6012.4016.5045.8338.5815.5216.551.1318.820.393780.13-0.66345.65-6.046.2611.375.31
Qiagen NV1.36bn11.71m9.70bn5.20k1,146.884.3252.097.130.03640.03645.909.670.30192.894.28266,657.600.26021.400.31531.5766.5865.320.8624.791.508.290.3943--1.642.57-121.77--23.16--
argenx SE47.58m-456.20m9.82bn188.00------206.48-10.40-10.401.10--------253,090.40---15.94---17.87-----958.79-197.24---5.09----224.8479.39-144.54--195.59--
DiaSorin SpA738.35m186.47m10.52bn1.97k55.5711.6142.6914.253.383.3813.4916.190.69611.265.01380,788.6017.5816.1120.5618.7469.0068.3925.2622.292.63144.810.029533.205.559.7411.1315.8912.689.63
Data as of Oct 23 2020. Currency figures normalised to Galapagos NV's reporting currency: Euro EUR

Institutional shareholders

17.91%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 31 Dec 20192.75m4.21%
Capital Research & Management Co. (World Investors)as of 30 Sep 20202.09m3.19%
The Vanguard Group, Inc.as of 30 Sep 20201.45m2.23%
Capital Research & Management Co. (Global Investors)as of 30 Sep 20201.09m1.66%
Norges Bank Investment Managementas of 31 Dec 2019977.99k1.50%
Invesco Advisers, Inc.as of 30 Sep 2020823.32k1.26%
T. Rowe Price International Ltd.as of 30 Sep 2020779.60k1.19%
Federated Global Investment Management Corp.as of 30 Jun 2020756.56k1.16%
BlackRock Fund Advisorsas of 08 Oct 2020579.66k0.89%
Sands Capital Management LLCas of 30 Apr 2020405.69k0.62%
More ▼
Data from 31 Dec 2019 - 30 Sep 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.